. 2021 Apr 12;95(9):e02165-20. doi: 10.1128/JVI.02165-20

TABLE 1.

Baseline characteristics of study participants

Participant characteristic	Placebo (n = 35)	Vaccine (n = 63)	Total (n = 98)
Age (yrs)^a	44 (38; 49)	46 (36; 51)	45 (38; 51)
Male, n (%)	30 (86)	56 (89)	86 (88)
Time since first positive serology (in yrs)^a	7 (5; 13)	8 (4; 14)	7 (4; 14)
Nadir CD4⁺ count (per mm³)^a	390 (335; 502)	389 (332; 480)	390 (334; 480)
CD4⁺ count at baseline (per mm³)^a	844 (684; 1,060)	840 (744; 1,018)	842 (733; 1,045)
RNA zenith (log₁₀ cp/ml)^a	5.1 (4.8; 5.6)	5.0 (4.4; 5.4)	5.0 (4.5; 5.4)
RNA at baseline (log₁₀ cp/ml)^a	1.6 (1.6; 1.6)	1.6 (1.6; 1.6)	1.6 (1.6; 1.6)

Median (Q1; Q3).